Magdalena brings investment and board experience from Syncona Limited and McKinsey & Company. She currently serves as an investor board director across several therapeutics companies.
Michael brings life sciences executive, company building, and investment experience. He currently serves as vice president and head of strategy for biopharma at Curium Pharma following roles at Syncona and L.E.K. Consulting.
The financing round was led by Sofinnova Partners and will fund upcoming clinical trials for kidney disease treatments.
"Our investment into Purespring Therapeutics fits perfectly into our strategy to support the UK’s life sciences and is the type of UK growth company which could benefit further by unlocking the potential of institutional investment. We need to support companies like Purespring as they go through development and trials before coming to market.Providing that capital simultaneously stimulates growth and helps to solve pressing medical challenges that will deliver long-term outcomes for generations to come."
— Ian Connatty, Managing Director, Direct & Co-Investment
The Series A round was backed by Syncona Investment Management and Cambridge Innovation Capital to support pipeline progression and team expansion.
"I believe that Mosaic is ideally positioned to resolve the complexity of cancer, to discover and develop targeted therapies that address areas of high unmet need. The people, platform, connection to a world-leading genomics research institute, and strong investor partnerships are truly best in class. To receive funding from such high calibre investors is testament to the potential of Mosaic’s technology and multidisciplinary team, as well as the exceptional support provided by the Wellcome Sanger Institute."
The biotechnology firm has raised £96m in new capital to advance its gene therapy pipeline and manufacturing capabilities.
"The potential of gene therapy to change patients’ lives has never been greater and we are delighted to have leading US and European biotechnology investors join us in this extended Series C financing,"
The Series A round was led by Syncona and included a £1m investment from the UCL Technology Fund.
"It’s really exciting to be in at the start of something that could potentially change the way things are done. By bringing together academia and commerce, Quell Therapeutics will be at the cutting edge of the research and development of this important field."
